A pharmaceutical composition comprising； an aqueous carrier； 0.1 mg / ml to 20 mg / ml of the composition of a pharmaceutically acceptable salt of a peptide comprising consecutive amino acids having the sequence (i) TGYYX1X2X3X4XSQSPEKSLEWIG (SEQ ID NO: 11) where X1 is Met, Ala or Val； X2 is Gln, Asp, Glu or Arg； X3 is Trp or Ala； X4 is Val or Ser； and X5 is Lys, Glu or Ala； (ii) EINPSTGGX6X7X8X9X10X11X12KAKAT (SEQ ID NO: 12) where X6 and X7 are each Thr, Val or Ala； X8 is Tyr or Phe； X9 is Asn or Asp； X10 is Gln or Glu； X11 is Lys or Glu, and X12 is Phe or Tyr； (iii) YYCARX13X14X15X16PYAX17X18YWGQGS (SEQ ID NO: 13) where X13 is Phe, Thr or Gly； X14 is Leu, Ala or Ser； X15 is Trp or Ala； X16 is Glu or Lys； X17 is Met or Ala, and X18 is Asp, Lys, or Ser； (iv) GYNX19X20X21X22X23X24SHGX25X26LEWIG (SEQ ID NO: 14) where X19 is Met or Ala； X20 is Asn, Asp or Arg； X21 is Trp or Ala； X22 is Val or Ser； X23 is Lys or Glu； X24 is Gln or Ala； X25 is Lys or Glu, and X26 is Ser or Ala； (v) YYCARX27X28X29YGX30X31X32GQTL (SEQ ID NO: 15) where X27 is Ser or Phe； X28 is Gly or Ala； X29 is Arg, Ala or Glu； X30 is Asn or Asp； X31 is Tyr or Phe, and X32 is Trp, His or Ala； (vi) X33YYWSWIX34QX35PX36X37GX38EWIG (SEQ ID NO: 16) where X33 is Gly or Thr Gly； X34 is Arg or Lys； X35 is Pro or Ser； X36 is Gly or Glu； X37 is Lys or Asp； and X38 is Glu, Leu, or Ser； (viii) FSGYYWS (SEQ ID NO: 8)； (ix) EINHSGSTNYKTSLKS (SEQ ID NO: 9)； or (x) GLLRGGWNDVDYYYGMDV (SEQ ID NO: 10), and a substituted β-cyclodextrin as a selected solubility enhancer y, where both the peptide and the solubility enhancer are dissolved in the aqueous carrier； and where the composition has a pH between 4 and 9.Una composición farmacéutica que comprende； un portador acuoso； de 0.1 mg/ml a 20 mg/ml de la composición de una sal farmacéuticamente aceptable de un péptido que comprende aminoácidos consecutivos que tienen la secuencia (i) TGYYX1X2X3X4XSQSPEKSLEWIG (SEQ ID NO:11) donde X1 es Met, Ala o Val； X2 es Gln, Asp, Glu o Ar
